The global obesity-diabetes drugs market is estimated to be worth USD 56,739.0 million in 2024 and is projected to reach a value of USD 97,567.47 million by 2034, expanding at a CAGR of 5.6% over the assessment period.
The obesity-diabetes drugs market witnessed a lucrative growth in recent years. The industry witnessed a lucrative growth majorly due to the rising prevalence of diabetic disease among younger population. These rise in prevalence is primarily due to sedentary lifestyle followed by young population contributing to the increase in number of people suffering from type 2 diabetes.
| Attributes | Description |
|---|---|
| Estimated Global Obesity-Diabetes Drugs Market Size (2024E) | USD 56,739.0 million |
| Projected Global Obesity-Diabetes Drugs Market Value (2034F) | USD 97,567.4 million |
| Value-based CAGR (2024 to 2034) | 5.6% |
Other factors such as ethnicity, age, lack of physical activity, unhealthy diet and behavioural habits in addition to genetic and family history are few other factors that lead to the development of diabetes condition.
For instance, according to the statistics published by Centers for Disease Control and Prevention in April 2023, 38 million individuals in America are suffering from diabetes among which 90 to 95% of them have type 2 diabetes. The rising prevalence of diabetes has brought opportunities for pharmaceutical companies engaged in the manufacturing and development of obesity diabetes drugs.
Combination therapy have emerged as a significant trend in the obesity-diabetes drugs market. Pharmaceutical firms are increasingly concentrating on developing medications that treat various elements of metabolic diseases at once.
This method seeks to improve efficacy, increase patient adherence, and perhaps minimize adverse effects. Combination drugs provide excellent potential for more successful obesity and diabetes management, indicating a trend toward holistic therapy approaches.
One type of combination therapy that exists in the obesity-diabetes drugs market is the simultaneous targeting of appetite management and glucose metabolism. Drugs that combine components such as GLP-1 receptor agonists as well as SGLT-2 inhibitors have a dual mode of action, promoting weight reduction and glycaemic management in individuals with both disorders, reflecting the changing landscape of treatment methods.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Product Portfolio Expansion by Receiving Approval for New and Existing Drugs
Growing number of obesity diabetes cases has brought new opportunities for key players in the industry to expand their product portfolio by receiving approval for their drugs in the industry. For instance, in May 2022, Eli Lilly and Company received approval from the United States Food and Drug Administration (FDA) for their Mounjaro drug which is a GLP-1 receptor agonist and is indicated for improving the glycemic controls in adults with type 2 diabetes.
Rising Prevalence of Obese People Augments the Demand for Obesity-Diabetes Drugs
Individuals sitting for long continuous hours in front of screen, reduced number of physical activities, and the increased accessibility and consumption of wide range of unhealthy food items are some of the major reasons contributing to increase in number of people suffering from obesity diabetes. For instance, according to a press released by the Economic Times in April 2023, poor and unhealthy diet has contributed to over 14.1 million cases of type 2 diabetes in the year 2018 which represented over 70.0% of new diagnosis globally.
Emerging Trends in Personalized Nutrition and Functional Supplements
The landscape of obesity diabetes drugs is rapidly evolving, driven by increasing number of people following sedentary lifestyle and opting for products that can aid them in management of their obesity-diabetes. In order to reach more number of people seeking for the treatment and expand their customer base many of the key players operating in the industry are focusing on strategic collaboration for raising awareness of the disease through new diabetic awareness program.
There is also growing preference for personalized medicines that are tailored to individual needs, reflecting a shift in the approach to obesity-diabetes management. Recognizing that one-size-fits-all is not the way to go, more consumers and manufacturers are gravitating toward personalized obesity-diabetes drugs.
Global obesity-diabetes drugs sales increased at a CAGR of 3.9% from 2019 to 2023. For the next ten years, projections are that expenditure on obesity-diabetes drugs will rise at 5.6% CAGR
The rising prevalence of obesity diabetes among younger population has significantly contributed to increase in demand for drugs that are effective in the management of their chronic condition. The rising prevalence has created opportunities for new players to develop and launch their new product to the industry and mark their presence in the existing concentrated industry.
For instance, in January 2024, Adipo Therapeutics, a late stage, preclinical biopharmaceutical company raised a funding of USD 1.9 million in the bridge fund round. The company has planned to invest this amount for the advancement of their asset ADPO-002, a first in class weight loss and diabetes drug.
Going forward the growing focus of emerging nations on improving the affordability of the healthcare services surges the demand for obesity-diabetes drugs in the industry. Surplus, to this, the marketing initiatives taken by pharmaceutical manufacturers for spreading awareness of obesity-diabetes in the untapped markets of the developing regions with an aim of expanding their geographical footprint in the industry further propels the industry growth.
Principal Consultant
The Tier 1 players in this industry dominate the industry and are expected to acquire 52.5% market share in 2024. A few of the Tier 1 players include Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi, Novo Nordisk A/S, AstraZeneca, Novartis, Pfizer, Merck & Co., Inc., Takeda Pharmaceuticals, Bayer AG, and Janssen Pharmaceuticals Inc. Tier 1 companies in the worldwide obesity-diabetes drugs market are using their substantial research and development skills to create novel treatments.
They make considerable investments in clinical studies to demonstrate efficacy and safety, obtain regulatory clearances, and form strategic alliances to broaden industry reach. They use aggressive marketing methods to promote their products and gain a greater piece of the profitable industry.
The Tier 2 companies in this industry include companies like Vertex Pharmaceuticals Incorporated, Mankind Corporation, Xeris Pharmaceuticals, and Amphastar Pharmaceuticals, Inc. All of them together are going to constitute an industry share of 28.3% in 2024.
Tier 2 pharmaceutical firms are adopting new drug delivery methods or specialty therapeutic areas to differentiate themselves. They want to capitalize on industry shortages by providing customized therapies or enhanced formulations. They may seek collaborations with larger companies or enter into license arrangements to have access to the resources and expertise required for product development as well as commercialization.
The following table shows the estimated growth rates of the top three markets. China and India are set to exhibit high obesity-diabetes drugs consumption, recording CAGRs of 5.7% and 6.4%, respectively, through 2034.
| Countries | CAGR 2024 to 2034 |
|---|---|
| The United States | 4.7% |
| China | 5.7% |
| Germany | 3.8% |
| The United Kingdom | 4.0% |
| India | 6.4% |
The obesity-diabetes drugs industry in the United States held a market share of 24.8% and is projected to exhibit a CAGR of 4.7% during the assessment period.
The growing number of people following sedentary lifestyle in the country is majorly contributing to the growth of the industry in the country. The support of healthcare insurance coverage extended by the government of the United States, propels the growth of the industry.
For instance, according to an article published by the National Archives and Records Administration in March 2023, The Office of the Federal Register (OFR) of the National Archives and Records Administration (NARA) have expanded the healthcare coverage nationwide and have lowered the healthcare cost for Americans. They also have a vision of preventing and reducing the pervasiveness of diabetes across the United States by 2030.
Obesity-diabetes drugs market held a industry share of 3.7% in Germany and is calculated to rise at a value CAGR of 3.8% during the forecast period.
The ageing population of the country along with increasing number of young populations following sedentary lifestyle contribute to the rising prevalence of obesity-diabetic patients. For instance, according to an article published by Deutsches Zentrum fur Diabetesforschung in February 2019, an approximate of 7.2% of the population in Germany is suffering from diabetes among which more common is type 2 diabetes.
The growing prognosis has contributed to the growing demand for trained experts and the establishment of new specialized centers in the country, which is ultimately escalating the demand for obesity-diabetes drugs in the industry.
Consumption of obesity-diabetes drugs in Japan is projected to increase at a value CAGR of 5.7% over the next ten years. By 2034, the industry size is forecasted to reach USD 9,458.8 million, with a current share of 9.4% in the global industry in 2024.
The increasing number of people consuming unhealthy diet with their limited focus on performing physical activities have majorly contributed to increase in number of overweight and obese population in China. Such factors put Chinese population at the increased risk of type 2 diabetes.
For instance, according to the statistics published by World Health Organization (WHO), more than one-third of the Chinese adult population is overweight, while 7% of adults are obese, which puts them at the risk of developing type 2 diabetes.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Segment | Drug Therapy (Therapy Type) |
|---|---|
| Value Share (2024) | 55.9% |
The ability of drug therapy to aid patients in controlling the blood sugar levels in an effective manner has attributed to its increased industry share. Its safety and tolerance in among all age groups has further contributed to its increased industry share. For instance, according to an article published by National Library of Medicine in January 2021, metformin remains the preferred first line pharmacological drug for the treatment of type 2 diabetes.
| Segment | Institutional Sales (Sale Channel) |
|---|---|
| Value Share (2024) | 39.7% |
Institutional sales channel accounted for a significant industry share and dominated the industry. The segment is anticipated to advance at 4.7% CAGR during the projection period.
The institutional segment consists of sub-segment including hospitals, specialty clinics and others. The hospital segment accounted for the major share of the industry owing to the increasing number of patients suffering from obesity-diabetes contributing to increase in number of footfall of patients to the hospital.
In the dynamic landscape of the obesity-diabetes drugs market, key companies operating in the industry are focusing on research and development and launch of new products to the industry. The major aim of these players is to expand their product portfolio and strengthen their product portfolio in the industry. Many of the players are also focusing on strategic acquisitions for expansion of their product portfolio.
For instance
As per product type, the industry has been categorized into drug therapy (Meglitinides, sulfonylureas, Dipeptidyl-peptidase 4 (DPP-4) inhibitors, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors, bile acid sequestrants and GLP-1 receptor agonists), and insulin therapy (rapid acting insulin, short acting insulin, intermediate acting insulin, long acting insulin and biphasic insulin.
This segment is further categorized into oral administration, nasal administration and parenteral administration (subcutaneous, intramuscular and intravenous).
Different sales channels include Institutional sales (hospitals, specialty clinics, and others), retail sales (retail pharmacies, and drug stores) and online pharmacy.
Industry analysis has been carried out in key countries of North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa.
The global obesity-diabetes drugs market is estimated at a value of USD 56,739.0 billion in 2024.
Sales of obesity-diabetes drugs increased at 3.9% CAGR between 2019 and 2023.
Eli Lilly and Company, Sanofi, Novo Nordisk A/S, AstraZeneca, Xeris Pharmaceuticals, Novartis, Pfizer, and GLENMARK PHARMACEUTICALS LTD are some of the leading players in this industry.
The North American industry is projected to hold a revenue share of 27.5% in 2024.
Europe to hold 26.3% share of the global obesity-diabetes drugs market in 2024.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Therapy 5.2. By Route of Administration 5.3. By Distribution Channel 5.4. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapy 6.1. Drug Therapy 6.1.1. Meglitinides 6.1.2. Sulfonylureas 6.1.3. Dipeptidyl-peptidase 4 (DPP-4) inhibitors 6.1.4. Biguanide 6.1.5. Thiazolidinediones 6.1.6. Alpha-glucosidase inhibitors 6.1.7. Sodium-glucose co-transporter 2 (SGLT2) inhibitors 6.1.8. Bile acid sequestrants 6.1.9. Incretin mimetic (GLP-1 receptor agonists) 6.2. Insulin Therapy 6.2.1. Rapid Acting Insulin 6.2.2. Short Acting Insulin 6.2.3. Intermediate Acting Insulin 6.2.4. Long Acting Insulin 6.2.5. Biphasic Insulin 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration 7.1. Oral Administration 7.2. Nasal Administration 7.3. Parenteral Administration 7.3.1. Subcutaneous 7.3.2. Intramuscular 7.3.3. Intravenous 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel 8.1. Institutional Sales 8.1.1. Hospitals 8.1.2. Specialty Clinics 8.1.3. Others 8.2. Retail Sales 8.2.1. Retail Pharmacies 8.2.2. Drug Stores 8.2.3. Online Pharmacies 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. East Asia 9.6. South Asia and Pacific 9.7. Middle East and Africa 10. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Sales Forecast 2024 to 2034 by Therapy, Route of Administration, and Distribution Channel for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Boehringer Ingelheim International GmbH. 19.2. Eli Lilly and Company 19.3. Sanofi 19.4. Vertex Pharmaceuticals Incorporated 19.5. Novo Nordisk A/S 19.6. AstraZeneca 19.7. MannKind Corporation 19.8. Xeris Pharmaceuticals 19.9. Amphastar Pharmaceuticals, Inc. 19.10. Novartis 19.11. Pfizer 19.12. Dr. Reddy’s Laboratories 19.13. LUSOCHIMICA S.p.A. 19.14. Merck & Co., Inc., 19.15. Takeda Pharmaceuticals 19.16. Bayer AG 19.17. GLENMARK PHARMACEUTICALS LTD. 19.18. Janssen Pharmaceuticals Inc.
Explore Healthcare Insights
View Reports
Obesity-Diabetes Drugs Market
